Classification of Uremic Toxins and Their Role in Kidney Failure

Mitchell H. Rosner,1 Thiago Reis,2,3 Faeq Husain-Syed,4 Raymond Vanholder 6 Colin Hutchison,6,7 Peter Stenvinkel,8 Peter J. Blankestijn,9 Mario Cozzolino 10 Laurent Juillard,11,12 Kianoush Kashani,13,14 Manish Kaushik,14 Hideki Kawanishi,15 Ziad Massy,16,17 Tammy Lisa Sirich,18,19 Li Zuo,20 and Claudio Ronco 21,22

Abstract
Advances in our understanding of uremic retention solutes, and improvements in hemodialysis membranes and other techniques designed to remove uremic retention solutes, offer opportunities to readdress the definition and classification of uremic toxins. A consensus conference was held to develop recommendations for an updated definition and classification scheme on the basis of a holistic approach that incorporates physicochemical characteristics and dialytic removal patterns of uremic retention solutes and their linkage to clinical symptoms and outcomes. The major focus is on the removal of uremic retention solutes by hemodialysis. The identification of representative biomarkers for different classes of uremic retention solutes and their correlation to clinical symptoms and outcomes may facilitate personalized and targeted dialysis prescriptions to improve quality of life, morbidity, and mortality. Recommendations for areas of future research were also formulated, aimed at improving understanding of uremic solutes and improving outcomes in patients with CKD.

Background
Uremia is a broad term that has been variably used to describe the buildup of metabolic waste products, such as urea, that occurs with diminished kidney function. Along with the retention of metabolic waste products, patients with advanced kidney disease typically experience a constellation of symptoms that may include nausea, vomiting, fatigue, anorexia, muscle cramps, pruritus, mental status changes, and others, which lead to a reduced quality of life and excess morbidity and mortality. Given the retention of metabolic waste products with advanced kidney disease, there has been much interest in using dialysis techniques to remove these substances with the hope that symptoms and outcomes would also improve. However, this goal has only been partially achieved, and outcomes for patients with kidney disease remain suboptimal. Although our knowledge of solutes that build up with uremia has increased, there is a growing recognition that dialysis prescriptions (both hemodialysis and peritoneal) may not be effective in their removal. Furthermore, technological advances, such as the development of new hemodialysis membranes and the ability to perform high efficiency hemodiafiltration, enable the removal of molecules from the body up to a mass of approximately 50 kDa (1). Besides, other new technologies are being developed to remove toxins that build up with abnormal kidney function (2).

In light of these developments, an expert conference was convened to identify limitations in the definition and classification of uremic retention solutes and toxins. Experts in the field were tasked with a comprehensive review of the current definition and classification of uremic retention solutes, and posed several critical questions and recommendations to define these toxins better and map future studies for improving outcomes.

Materials and Methods
A diverse panel of clinicians and researchers representing experts in the field of uremia and uremic toxins were identified and invited by the conference chair (C.R.) to participate. In addition, a few individuals were chosen on the basis of experience in managing consensus processes. The conference was held virtually, over 3 days from November 30 to December 2, 2020, with additional small group sessions over the subsequent weeks. This consensus meeting used a modified Delphi method to achieve consensus, as previously described (3).

The consensus conference began with a preconference comprehensive literature search and appraisal of scientific evidence to identify key themes that are central to uremia and uremic toxins. Conference participants were divided into three workgroups (Supplemental Table 1) and were tasked with addressing the following themes: critical appraisal of limitations in the current definition/classification of uremic retention solutes; rationale for updating definition and classification of uremic retention solutes and molecules of interest in the field of maintenance hemodialysis;
and proposal of a new classification of solutes of interest in
uremia and hemodialysis. Literature searches were per-
formed using the National Institutes of Health PubMed plat-
form. Individual workgroups presented their output to con-
ference participants during the three online plenary sessions
for debate, discussion, and suggested revisions. In addition,
recommendations for research were formulated for all key
areas. The final product was then assessed and aggregated
in a videoconference session attended by all attendees, who
approved the consensus recommendations. A detailed de-
scription of the methodology is provided in the Supplemental
Methods.

Redefining Uremic Toxins

Rationale. In 2003, the European Uremic Toxin (EUTox)
Work Group proposed five criteria for an organic solute to
be classified as a uremic toxin (Figure 1, left column) (4). Inor-
ganic solutes (e.g., water, potassium, sodium, magnesium,
phosphate) were excluded in these criteria given the avail-
able literature on these solutes and their divergent intradia-
lytic removal patterns from other solutes of interest.
The current view of uremic toxicity incorporates many
solutes that are retained during kidney failure and have dif-
ferent physiochemical characteristics and diverse adverse
effects on biologic systems (5). Moreover, there are differ-
ences in toxicity of solutes, depending on whether a solute
is studied alone or in conjunction with other solutes that
may interact in complex ways (6,7). Besides, protein-bound
solutes exhibit a large variation in their binding affinities to
various plasma proteins (8,9), and toxicity may be exerted
by the free fraction or the total concentration of these sol-
utes (10). Undisputable proof of the toxicity of a specific
solute can in principle only be obtained if selective removal
is linked with improved outcomes and amelioration of
symptoms, but such studies have been conducted only for
a few uremic toxins (10); in those patients, proof of toxicity
is seldom unequivocal, likely because the effect of specific
toxins may be superseded by that of other solutes with over-
lapping biologic effects and which may interact in various
ways (11).

By 2012, EUTox listed 146 uremic retention solutes (4,8).
New technologies enable expansion of the list, creating a
more comprehensive picture of uremic toxicity than was ini-
tially appreciated (6,11,12). In this context, the question was
raised of whether the current definition of a uremic toxin
can be maintained or requires revision. We concluded that
modifications are necessary to accommodate new advances
in the field, especially with the development of newer hemo-
dialysis techniques. Figure 1 summarizes the current defini-
tion, the terminological limitations of that definition, and the
proposed update.

Recommendations.

1. We suggest the current definition of uremic toxins should
be adapted in terminology to account for the growth in
knowledge in the field (Figure 1).
2. We suggest the scope of the definition should remain
limited to organic solutes.

Physicochemical Classification of Uremic Toxins

Rationale. In 2003, EUTox categorized uremic toxins
according to their physicochemical characteristics that affect
clearance during hemodialysis. This classification was essen-
tially inspired by the need to simplify and organize uremic
toxicity concepts within a framework of therapeutic removal
approaches, mainly by hemodialysis. These classes include
small water-soluble compounds with low molecular mass

---

**Figure 1. | Definition of uremic toxins.** The left panel represents the current definition of uremic toxins, with the bold text indicating termi-
ology that we identified as needing an update. The middle panel elaborates on the limitations associated with the identified terms. The right
panel shows the newly proposed definition of uremic toxins.
(<500 Da), protein-bound solutes, and so-called middle molecules (≥500 Da) (13). Of note, the term middle molecule is a misnomer as it refers to peptides with a low molecular weight. The term was likely partially inspired by the removal pattern of hemodialysis membranes used at the time of formulation of the middle molecule hypothesis (14).

**Statement 1. The Current Physicochemical Classification of Uremic Toxins Does Not Adequately Address or Reflect How Current/Modern Hemodialysis Technologies (Mechanisms of Adsorption, Convection, and Diffusion) Remove Toxins.** The current physicochemical subdivision can be considered artificial because there is a continuum in the molecular weight of uremic solutes, and any cutoff on the basis of molecular weight is arbitrary (10). Besides, the degree of protein binding for these uremic solutes is variable and complicates any schema based solely on molecular weight. Nevertheless, because hemodialysis remains the most frequently applied therapeutic strategy to reduce the concentration of uremic toxins in advanced CKD, the most practical classification approach is on the basis of the principles of removal patterns by hemodialysis, noting it only applies to conventional hemodialysis, and not to peritoneal dialysis or hemodialysis time frames deviating from typical 4-hour thrice-weekly sessions (15,16). Also of note, the original classification does not account for the compartmental partitioning behavior of solutes within the body (17) or alternative strategies to decrease uremic toxin concentration (e.g., preservation of residual kidney function [18,19], adsorptive techniques [20], or strategies aimed at decreasing solute generation [21–23]). Finally, it should be acknowledged that any classification on the basis of dialysis strategies does not take into account that uremic signs and symptoms in advanced kidney disease may be present before the initiation of dialysis.

The mechanism of adsorption to hemodialysis membranes plays a role in removing uremic toxins, although membranes with truly enhanced adsorptive properties are still in the pipeline (20,24–29). Concerning the clinically available membranes, a marked reduction in the sieving coefficient for solutes with molecular mass >12 kDa demonstrates the adsorptive phenomenon of membrane caking derived from the deposition of plasma proteins (albumin-bound or soluble uremic toxins included) obstructing some pores, causing a time-dependent loss of efficiency during the hemodialysis session (30).

Newer hemodialysis membranes are likely to change the ability to remove higher molecular weight solutes that may be toxic. The ability to remove larger uremic toxins relies largely on convection. The high-flux dialyzer, when applied in the hemodialysis modality, has a molecular mass cutoff of 25 kDa (31), being boosted up to 30 kDa when in hemodiafiltration mode (32). A new class of membranes is the medium cutoff membrane, with a cutoff of 56 kDa, a mean pore radius of 5 nm, and a fiber inner diameter of 180 μm (33). As a comparison, the high-flux membrane has a mean pore radius of 3.9 nm and an inner diameter of approximately 200 μm (1,31,33,34). Clearance is more efficient for larger molecules (25–58 kDa) with medium cutoff membranes than it is for high-flux membranes. Clinical trials have consistently demonstrated increased clearance of larger molecular weight molecules, such as complement factor D, free k light chains, TNF-α, and β2-microglobulin (35,36). We believe the classification of middle molecules should include the effect of different hemodialysis membranes on their clearance, ultimately allowing the personalization of therapies. We recognize this approach is limited in that it is focused solely on hemodialysis versus other forms of KRT, such as peritoneal dialysis and transplantation.

**Recommendation.**

1. We suggest the definition of uremic toxins should be on the basis of hemodialysis strategies, membranes, and removal patterns, acknowledging that any classification on the basis of cutoff values and/or molecular spatial configuration or charge would be arbitrary and likely will need to be changed as technological development changes solute removal patterns.

**Classification on the Basis of Toxicity**

**Rationale.** Uremic toxicity negatively affects multiple organ systems and metabolic pathways (Figure 2); cardiovascular damage (37), increased susceptibility to infection (38), and neurologic manifestations (39) are major factors affecting mortality and quality of life of patients with CKD. However, the current physicochemical classification of uremic toxins provides no insight into where benefit may come from increased clearance of a class of uremic toxins, or where problems may lie by inadequate clearance of a class of uremic toxins.

**Statement 2. The Current Physicochemical Classification of Uremic Toxins Does Not Adequately Reflect the Biologic Consequences of the Toxins and Is Not Able to Identify which Toxins Possess the Most Clinical Relevance.** Wolley and colleagues (40) reviewed the breadth of effect for one group of uremic toxins, a subgroup of middle molecules with molecular masses >15 kDa. The authors demonstrated how these molecules are involved in chronic inflammation, cardiovascular disease, secondary immunodeficiency, and symptom burden. Their review emphasizes that a physicochemical classification of uremic toxins does not aid clinicians in addressing a specific complication of kidney failure. For example, in a patient at high risk of cardiovascular diseases, there will be involvement of uremic toxins from small water-soluble, middle-molecule, and protein-bound groups. Likewise, for the clinicians trying to improve the outcomes for a patient with recurrent infections, they will have to target uremic toxins from all three groups (water soluble, middle molecules, and protein bound). There may therefore be a logic to looking at a reclassification of uremic toxins on the basis of clinical consequences.

In 2018, a scoring system for uremic retention solutes was developed to classify solutes according to the experimental and clinical evidence of their toxicity (10). This unique classification was on the basis of objective and reproducible criteria and considered most uremic solutes then known (Table 1) despite limitations (e.g., it is a scoring system on the basis of the number of conclusive studies). Thus, solutes that are studied most frequently have a higher likelihood of reaching a high score; the classification lacks systematic literature analysis, it provides a framework for defining target molecules for future uremic toxicity analyses and removal studies. The expert group considered other classification systems, but felt this was the most evidence-based approach available.
**Recommendations.**

1. We suggest using the 2018 classification system (10) that reflects the degree of known toxicity on the basis of published peer-reviewed literature to define the pathophysiologic effect of each uremic retention solute. Periodic updates will be required as new evidence of the toxicity of solutes becomes available, and new solutes are identified.

2. We suggest the pathophysiologic effect of each uremic toxins (e.g., inflammatory, cardiovascular) and solute origin (e.g., intestinal generation, post-translational modification) should be stated wherever available.

3. We suggest focusing on a limited number of key body system effects that are the most prominent in uremia, such as cardiovascular damage, susceptibility to infection, and neurologic manifestations for pathophysiologic classification.

**Classification on the Basis of Patient Outcomes**

**Rationale.** In addition to the high morbidity and mortality associated with kidney failure, patients have a high symptom burden. Studies have demonstrated that reducing the symptom burden is as, if not more, important to many patients than an extended survival. Therefore, there has been much interest in recent years in developing robust, reproducible methods (41–44) to measure the patient experience. Additionally, there are now coordinated international research programs (45) targeting methods for improving what patients with kidney failure experience. However, the current classification of uremic toxins does not include patient experience or outcomes. The current uremic toxins classification does not help clinicians prescribe a dialysis regime for a patient with restless leg syndrome, fatigue, or prolonged recovery time after a dialysis session. Therefore, it would now be logical to look at the classification of uremic toxins in light of the symptoms and patient outcomes they cause. A classification such as this could then allow dialysis prescriptions to be specific to individual patient complaints, such as pruritus or restless leg syndrome.

**Statement 3. The Current Physicochemical Classification of Uremic Toxins Does Not Adequately Address Patient Experience or Outcomes and Does Not Reflect Personal Patient Characteristics by which the Dialysis Prescription Should Be Made (e.g., Targeting the Prevention of Cardiovascular Disease, Loss of Residual Kidney Function, Deterioration of Vascular Access, or Quality of Life).** Since the original classification of uremic retention solutes, significant advances have been made to understand their

---

**Table 1. Uremic toxins with the highest toxicity evidence score**

<table>
<thead>
<tr>
<th>Highest Evidence Score (4)</th>
<th>Second Highest Evidence Score (3)</th>
</tr>
</thead>
<tbody>
<tr>
<td>p-cresyl sulfate</td>
<td>Advanced glycation end products</td>
</tr>
<tr>
<td>β₂-microglobulin</td>
<td>Indoxyl sulfate</td>
</tr>
<tr>
<td>Asymmetric dimethyl arginine</td>
<td>Uric acid</td>
</tr>
<tr>
<td>Kynurenines</td>
<td>Ghrelin</td>
</tr>
<tr>
<td>Carbamylated compounds</td>
<td>Indole acetic acid</td>
</tr>
<tr>
<td>Fibroblast growth factor-23</td>
<td>Parathyroid hormone</td>
</tr>
<tr>
<td>IL-6</td>
<td>Phenyl acetic acid</td>
</tr>
<tr>
<td>TNF-α</td>
<td>Trimethyl methylamine-N-oxide</td>
</tr>
<tr>
<td>Symmetric dimethyl arginine</td>
<td>Retinol binding protein</td>
</tr>
<tr>
<td></td>
<td>Endothelin</td>
</tr>
<tr>
<td></td>
<td>Immunoglobulin light chains</td>
</tr>
<tr>
<td></td>
<td>IL-1β</td>
</tr>
<tr>
<td></td>
<td>IL-8</td>
</tr>
<tr>
<td></td>
<td>Neuropeptide Y</td>
</tr>
<tr>
<td></td>
<td>Lipids and lipoprotein*</td>
</tr>
</tbody>
</table>

Adapted from Vanholder et al. (10). The ranking was on the basis of the number of experimental and clinical studies showing toxicity with a downgrade if 25% of the retrieved studies showed no effect or a benefit. A score between 4 and 0 was possible, with only the toxins scoring 4 or 3 displayed in this table. Per score the toxins are ranked top to bottom according to the proven number of affected organ systems. *Post-transcriptional modifications.
clinical effect in uremia. For example, urea, once considered biologically inert, has been associated with insulin release (46), free radical production (47), apoptosis (48), and disruption of the intestinal barrier (49). Similarly, molecules such as β2-microglobulin, complement factor D, immunoglobulin free light chains, endothelin, and fibroblast growth factor-23 have been shown to have significant effects on the cardiovascular system, inflammation, and fibrosis (13,50–53). In contrast, studies demonstrating adverse effects of molecules, such as adiponectin, IL-10, leptin, resistin, or visfatin are lacking (54). The HEMO (55) and the MPO (56) studies suggested high-flux hemodialysis membranes compared with low-flux hemodialysis membranes are associated with lower risk of mortality in certain subgroups of patients with long dialysis vintage, diabetes, and serum albumin of ≤4 g/dl. Although not conclusive, these results indicate a potential advantage of increasing the spectrum of hemodialytic removal of uremic toxins to include larger molecules. It should be noted that the retention of inorganic solutes, which, per the definition, are not considered uremic toxins, and may offset or supersede any beneficial effects derived from the removal of organic solutes given their undisputed link to cardiovascular morbidity and mortality. The classification of uremic solutes does not express their clinical relevance, nor does it identify candidate molecules whose dialysis clearance and blood levels may be monitored to assure dialysis adequacy and improvement in clinical outcomes (10,13). Therefore, future classification attempts must aim to map patient profile or phenotype to a single or panel of biomarkers and suggest reduction or removal techniques that can be best utilized to decrease levels.

Recommendations.

1. Future studies should focus on correlating solute concentrations or the effect of interventions on solute concentrations with clinically relevant outcomes and outcomes of importance to patients.
2. Ideally, dialysis prescriptions would be tailored to improve these symptoms and quality of life on the basis of removal patterns of uremic solutes linked to symptoms and outcomes.

Assessment of Toxin Measurement and Removal Capacity

Rationale. A marker of solute removal should be linked to its toxicity (and improvement of symptoms with removal) and be representative of other toxins with comparable characteristics. Given the unpredictable effect of kinetics on removing various uremic toxins in intermittent dialysis strategies such as maintenance hemodialysis (16,57,58), we suggest that (prehemodialysis) concentration after a sufficiently long equilibration is a better measure of toxin removal than clearance or pre- to postremoval ratio calculations. Depending on the efficiency of removal, multicompartamental solutes will need different equilibration times (Figure 3). An equilibration time of 4 weeks allows most solutes (except those with very low dialytic concentration reduction ratios, which are observed when the volume of distribution is large relative to the dialytic clearance) to reach equilibrium while minimizing the occurrence of confounders (e.g., loss of residual kidney function, need for antibiotics, changes in dialytic prescription, changes in dietary intake).

Recommendations.

1. For assessment of toxin removal by extracorporeal treatment, we recommend measuring the prehemodialysis concentration of a toxin after a period of equilibration (≥4 weeks).
2. For comparability reasons, we suggest using the same equilibration time (4 weeks) to study any other strategy than extracorporeal removal to decrease toxin concentration (e.g., medication, dietary intervention, xenobiotics, and others).

Proposal for a New Classification System of Uremic Solutes

Rationale. It should be emphasized that decreased uremic toxin clearance due to low GFR is not the sole reason for toxin accumulation in kidney failure. For example, excessive production of cytokines and soluble receptors due to local tissue inflammation is a major contributor to middle-molecule accumulation (54). Besides, gut dysbiosis generates a broad spectrum of uremic toxins (57). Thus, a broader view of uremic solutes that goes beyond simply retention with poor GFR is needed. Recent data regarding the origin of uremic toxins, and the new development of hemodialysis methods and new membranes with the ability to clear uremic toxins with specific characteristics, or by using drugs/molecules to facilitate the shift from bound fraction to free fraction (58), lead us to propose a new classification beyond the classic physicochemical classification.

Statement 4. New Measurement Tools for Uremic Toxins Are Needed in Each Class that Go Beyond Physicochemical Classification. Because the available tests (limited to a few relevant molecules, such as phosphate, urea, serum creatinine) are not sufficient for clinical needs, new validated biomarkers are needed. For example, the accumulation of toxins in the uremic milieu nurtures an intermediate inflamed phenotype related to oxidative stress, fibrosis, senescence, mitochondrial dysfunction, and tissue hypoxia that promote premature aging (59) by vascular calcification, left ventricular hypertrophy, osteoporosis, sarcopenia, frailty, and cognitive dysfunction. Thus, to better target the intermediate inflammatory phenotype, we suggest considering the kinetics of a wide range of uremic toxins in addition to the urea kinetics. The ideal biomarker should be inexpensive, easy to measure, globally available, correlate with severity of disease, and be sensitive to early subclinical disease, recovery, and response to therapy. We believe the new classification is clinically more relevant.

Recommendation.

1. The new classification schema must link uremic solutes to traditional clinical outcomes and quality of life measures, including pruritus, restless legs syndrome, and recovery time after dialysis (60,61).

We propose a panel of biomarkers representing each uremic toxin class (Figure 4). Small (<500 Da) water-soluble molecules and urea (60 Da) correspond to the criteria mentioned above and could be included in the biomarker panel. Creatinine (113 Da) could also be considered a biomarker of small
water-soluble toxins, but only if factors that are known to confound its concentration, such as age, muscle mass, Kt/V, and normalized protein catabolic rate are accounted for (62). However, it should be noted there is little evidence linking creatinine directly with uremic symptoms or outcomes. For evaluation of small-middle molecular mass (0.5–2 kDa) clearance, we recommend using parathyroid hormone (9.5 kDa) and \(b\)-2-microglobulin (11.8 kDa). For estimation of medium-middle (2–25 kDa) and large-middle (25–58 kDa) molecular mass clearance, we recommend analyses of \(\kappa\) (22.5 kDa) and \(\lambda\) (45 kDa) free light chains, respectively. Until validation of a more widely available estimate of protein-bound solutes, clearance of protein-bound solutes is best estimated by analyses of indoxyl sulfate and paraacetyl sulfate. It should be noted that residual kidney function can significantly contribute to the removal of solutes for which protein binding limits clearance by hemodialysis. Finally, it is important to recognize that the evidence base for use of some biomarkers is immature and requires additional study.

Importantly, studies linking removal of these biomarkers to clinical outcomes are required.

**Recommendation.**

1. Candidate biomarkers representing different types of uremic retention solutes should be identified and used as proxies to study various dialytic and nondialytic removal strategies.

**Statement 5. Available and Newer Dialysis Technology (Including Membranes) Must Be Measured for Its Effective Removal of Uremic Toxins in Each Class.** In recent years, the clearance profiles of the latest generation of hemodialyzer membranes have improved remarkably. Several characteristics should be considered for the evaluation of new membranes. These include new permeability indices, the hydrophilic or hydrophobic nature of membranes, adsorption capacity, and electrical potential (63).
Furthermore, molecular weight retention onset, molecular weight cutoff, and the mass transfer area coefficient should be measured (64). Some studies support the choice of high volume postdilution hemodiafiltration over the current dialysis techniques (65,66). Beyond diffusion and convection, the removal pattern of the uremic toxins by hemodialysis methods could be enhanced by adsorption techniques (58), or by using drugs or molecules to facilitate the shift from bound fraction to free fraction (67). Consideration of uremic toxin characteristics has an effect on treatment choice. Therefore, clinicians should consider molecular radius, electrical charges, protein binding solute characteristics, high versus low molecular weight, hydrophilic versus hydrophobic, endogenous versus exogenous, secretion by kidney tubules, and different volumes of distribution (68).

**Statement 6. Prototype Uremic Biomarkers Should Be Validated as New Measurement Tools of Uremic Toxicity.** Identifying prototype biomarkers that could be used to optimize the management of kidney failure is essential. Current methodologies for the evaluation of the adequacy of dialysis, such as Kt/V, should not be abandoned until high-quality clinical studies support the use of novel biomarkers. These biomarkers need to be linked to improving clinical outcomes, that is, they are directly or indirectly linked to uremic toxicity processes in vivo. These biomarkers need to predict uremic manifestations, provide information about mechanisms and prognosis, improve the safety of interventions to address uremia, or be used as a surrogate marker of a uremic toxin or clinical outcome. The relationship between the accumulation of uremic toxins, intervention, and outcome should be considered. Although the role of various uremic toxins in pathophysiological processes that drive morbidity has been widely studied, the extent of the effect after intervention is less clear. Moreover, the effect between a change in biomarkers and aspects of quality of life is virtually unexplored. Novel treatments should establish whether a change in uremic toxin biomarkers affects traditional clinical outcomes and whether it improves quality of life. In addition, the cost of using novel biomarkers must be assessed and be sensitive to resource-constrained environments to ensure widespread uptake.

Biomarkers need to be sensitive to subclinical toxicities and respond to extracorporeal or enhanced endogenous toxin removal. A multidimensional understanding of disease biology using omics technologies (genomics, transcriptomics, proteomics, cytometric, and metabolomics) and “big data” methodologies is necessary for understanding the complex pathophysiology of uremia (Supplemental Figure 1). After the relationship between uremia pathophysiology and target biomarkers is understood, a biomarker discovery
phase should follow, by testing candidate biomarkers in patients with CKD to identify biomarkers with the highest performance. The highest performers should be validated in a larger, diverse group of patients. In the next phase, studies need to assess the effect of biomarker-guided protocols on clinical outcomes. Finally, test platform development with rapid turnaround time, low cost, and high accuracy should be completed before implementation in clinical practice.

Research Recommendations. Given the many unknowns in the field of uremic toxins, the consensus group felt strongly that continued research was critical. A research agenda was identified and listed in Supplemental Table 2. This agenda links with the above statements and enhances the move away from the classification of uremic solutes based solely on physiochemistry and removal patterns on the basis of prior dialytic techniques and membranes. Adherence to the research agenda is likely to yield substantial increases in our knowledge base regarding the uremic syndrome and ultimately improve patients’ outcomes.

Summary
Advances in our understanding of uremic toxins and the availability of new hemodialysis membranes and techniques have led to a reappraisal of the definition and classification of uremic toxins. We recommend a more holistic classification that includes physicochemical characteristics and correlation to clinical symptoms and outcomes. Besides, the identification of representative biomarkers that correlate with removal patterns and are clinically relevant in terms of toxicity may lead to more personalized and targeted dialysis prescriptions and facilitate the search for nondialysis strategies that have the opportunity of improving the quality of life and outcomes for patients with advanced kidney disease. Validation of the novel classification will require big data methodologies, validation in external cohorts, and experimental evidence of toxicity. Of note, new data on uremic toxins and removal techniques are continuously being published and these recommendations may therefore require modifications as new results become available.

Disclosures
C. Hutchinson reports consultancy agreements with, receiving research funding from, and receiving honoraria from Baxter. C. Ronco reports consultancy agreements with Asahi, Astute, Baxter, B. Braun, Biomerieux, Bioporto, Cytosorbents, General Electric (GE), Jaftron, Medtronic, OCD, and Toray; receiving honoraria from Astute, Baxter, B. Braun, Estor, Fresenius, GE, Jaftron, Medtronic, and Toray; and reports serving as the Editor-in-Chief of Blood Purification and Contributions to Nephrology and Cardiorenal Medicine and as an Associate Editor of Nephrology Dialysis and Transplantation. H. Kawanishi reports receiving honoraria from Kyowa-Kirin Co. Ltd.; reports serving as a scientific advisor or member of PDOPPS Steering Committee; reports serving on the Editorial Boards of Blood Purification, Peritoneal Dialysis International, and The Journal of Vascular Access; and reports serving as president of International Society of Blood Purification. K. Kashani reports consultancy agreements with AM PHARMA; reports receiving research funding from La Jolla Inc.; and reports serving as a scientific advisor or member of GE, La Jolla Inc., and MediBeacon Inc. L. Juillard reports consultancy agreements with Amgen, Astellas, Baxter, Fresenius, Hemotech, Leo, Novartis, Otsuka, Sanofi, and Vifor; reports receiving research funding from Amgen, Baxter, and Sanofi; reports receiving honoraria from Amgen, Astellas, Baxter, Fresenius, Hemotech, Leo, Novartis, Otsuka, Sanofi, and Vifor; and serving as a scientific advisor or member of Amgen, Astellas, Baxter, Fresenius, Hemotech, Leo, Novartis, and Vifor. M. Cozzolino reports receiving research funding from Abbvie, Baxter, Keryx, and Shire; reports receiving honoraria from Abbvie, Amgen, Baxter, Shire, and Vifor-Fresenius; reports serving as a scientific advisor or member of and reports speakers bureau for Abbvie, Amgen, Keryx, Shire, and Vifor. M.H. Rosner reports consultancy agreements with Baxter; reports receiving research funding from Kadmon and National Institutes of Health; reports receiving honoraria from the American Society of Nephrology and Baxter; reports serving as an Editor-at-Large of CJASN; and reports serving as a scientific advisor or member of American Society of Nephrology and on the Data Safety Monitoring Boards of clinical trials sponsored by AstraZeneca, Reata, and Traverve. M. Kaushik reports receiving honoraria from and speakers bureau for Baxter Healthcare and Fresenius Medical Care; and serving as a member of ARA-EDTA, European Society of Intensive Care Medicine, International Society of Nephrology, NKF, Singapore Society of Nephrology, and Society of Transplantation Singapore. P.J. Blankestijn reports receiving consulting fees and receiving honoraria, fees paid to the institution, from Baxter and Medtronic; reports receiving research funding from Ablative Solutions, the European Commission, and Recor; and reports serving on the Editorial Board of Nephrology Dialysis Transplantation. P. Stenvinkel reports receiving consultancy fees, research grants, and speaker’s honoraria from Amgen, Astellas, AstraZeneca, Baxter Healthcare, Bayer, Fresenius Medical Care, Pfizer, Reata, and Vifor. R. Vanholder reports consultancy agreements with Baxter Healthcare, BBraun, Fresenius Medical Care, Jaftron, Kibow, and Nextkidney Project; has received travel support and honoraria from Baxter Healthcare and B. Braun Avitum; reports serving as an advisor to B. Braun Avitum, Baxter Healthcare, Debiotech, Fresenius Medical Care, Jaftron, Kibow, and the Dutch Kidney Foundation; and reports serving as a scientific advisor or member of European Kidney Health Alliance, International Scientific Advisory Board Dutch Kidney Foundation, JASN, Nature Reviews Nephrology, and Nephrology Dialysis Transplantation. T. Reis reports employment with Clinica de Doencas Renais de Brasilia; consultancy agreements with AstraZeneca, Baxter, Contatti Medical (CytoSorberts), and Eurofarma; and reports receiving honoraria and speakers bureau from AstraZeneca, Baxter, B. Braun, Contatti Medical (CytoSorberts), Eurofarma, and Jaftron. Z. Massy reports receiving research funding from Amgen, Baxter, the French government, Fresenius Medical Care, Genzyme-Sanoﬁ, GlaxoSmithKline, Lilly, Merck Sharp and Dohme-Chibret, and Otsuka and government support for CKD REIN project and experimental projects; reports receiving honoraria on consultation fees to charities or for travel from AstraZeneca, Baxter, and Genzyme-Sanoﬁ; and serving as a scientific advisor or member of Journal of Nephrology, Journal of Renal Nutrition, Kidney International, Nephrology Dialysis Transplantation, and Toxins. All remaining authors have nothing to disclose.

Funding
Support for the consensus conference was from Baxter Healthcare through an unrestricted educational grant to C. Ronco.

Acknowledgments
Baxter Healthcare did not participate in the meeting or have any role in the preparation of the consensus statements or manuscript.
Because Dr. Mitchell H. Rosner is an Editor-at-Large of CJASN, he was not involved in the peer review process for this manuscript. Another editor oversaw the peer review and decision-making process for this manuscript.

Supplemental Material
This article contains the following supplemental material online at http://cjASN.asnjournals.org lookup suppl/doi:10.2215/CJN.02660221/-/DCSupplemental.

Supplemental Methods.
Supplemental Table 1. Information regarding workgroups and work product.
Supplemental Table 2. Research recommendations for improving our understanding of uremic solutes, their dialytic removal, and their effect on clinical outcomes.
Supplemental Figure 1. Big data-driven discovery and validation of candidate uremic retention solutes.

References


Published online ahead of print. Publication date available at www.cjasn.org.
AFFILIATIONS

1 Division of Nephrology, University of Virginia Health System, Charlottesville, Virginia
2 Department of Nephrology, University of Brazil, Brasilia, Brazil
3 National Academy of Medicine, Rio de Janeiro, Brazil
4 Department of Internal Medicine II, Justus-Liebig-University Giessen, Giessen, Germany
5 Department of Internal Medicine and Pediatrics, University Hospital, Ghent, Belgium
6 Faculty of Medicine, University of Queensland, Herston, Australia
7 Department of Medicine, Hawke’s Bay District Health Board, Hastings, New Zealand
8 Renal Medicine, Karolinska University Hospital, Stockholm, Sweden
9 Department of Nephrology and Hypertension, University Medical Centre Utrecht, Utrecht, The Netherlands
10 Renal Division, Università degli Studi di Milano, Milan, Italy
11 University of Lyon, Villeurbanne, France
12 Hôpital E. Herriot, Lyon, France
13 Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota
14 Department of Renal Medicine, Singapore General Hospital, Singapore, Singapore
15 Department of Artificial Organs, Tsuchiya General Hospital, Hiroshima, Japan
16 INSERM U1018, Villejuif, France
17 Service de Néphrologie et Dialyse, Hôpital Universitaire Ambroise Paré, Boulogne-Billancourt, France
18 Nephrology Section, Veterans Affairs Palo Alto Health Care System, Palo Alto, California
19 Division of Nephrology, Stanford University School of Medicine, Stanford, California
20 Department of Nephrology, Peking University People’s Hospital, Beijing, China
21 Department of Medicine, University of Padova, Padova, Italy
22 Department of Nephrology, Dialysis and Transplantation, International Renal Research Institute of Vicenza, Vicenza, Italy